{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:51:50Z","timestamp":1791301910318,"version":"4.1.0"},"reference-count":186,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the most common chronic liver condition worldwide, closely linked to obesity, insulin resistance, and metabolic syndrome. It spans a spectrum from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, and hepatocellular carcinoma. This review examines the core metabolic disruptions\u2014particularly in lipid, glucose, bile acid, amino acid, and iron metabolism\u2014that drive MASLD pathogenesis. It also explores how genetic variants such as PNPLA3, TM6SF2, GCKR, HSD17B13, and MBOAT7 contribute to disease susceptibility and variability in clinical outcomes. The interaction between genetic background and metabolic stress is central to the heterogeneity seen in disease progression and treatment response. We further discuss persistent clinical challenges and summarize recent advances in drugs, natural compounds, and microbiota-based strategies. Finally, we highlight the promise of multi-omics approaches to better stratify patients and personalize management. A clearer understanding of the molecular and clinical complexity of MASLD will be key to developing more effective and individualized strategies for diagnosis and treatment.<\/jats:p>","DOI":"10.3389\/fendo.2025.1639064","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T04:17:58Z","timestamp":1757477878000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Metabolic and genetic mechanisms of metabolic dysfunction-associated steatotic liver disease: an integrative perspective from molecular pathways to clinical challenges"],"prefix":"10.3389","volume":"16","author":[{"given":"Jingyuan","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanna","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junchen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunshu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhai","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.7570\/jomes22021","article-title":"Recent epidemiology and risk factors of nonalcoholic fatty liver disease","volume":"31","author":"Huh","year":"2022","journal-title":"J Obes Metab syndrome"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"103043","DOI":"10.1016\/j.arcmed.2024.103043","article-title":"Global Prevalence of Nonalcoholic Fatty Liver Disease: An Updated Review Meta-Analysis comprising a Population of 78 million from 38 Countries","volume":"55","author":"Amini-Salehi","year":"2024","journal-title":"Arch Med Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00193-6","article-title":"Natural history and progression of metabolic dysfunction-associated steatotic liver disease","volume":"9","author":"Hagstr\u00f6m","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13098-020-00570-y","article-title":"NAFLD as a continuum: from obesity to metabolic syndrome and diabetes","volume":"12","author":"Godoy-Matos","year":"2020","journal-title":"Diabetol Metab syndrome"},{"key":"B7","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41575-023-00754-7","article-title":"Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment","volume":"20","author":"Llovet","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14694","article-title":"Developmental programming by maternal obesity: Lessons from animal models","volume":"38","author":"Schoonejans","year":"2021","journal-title":"Diabetic medicine: J Br Diabetic Assoc"},{"key":"B9","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1038\/s41467-018-06929-0","article-title":"The gut microbiota in infants of obese mothers increases inflammation and susceptibility to NAFLD","volume":"9","author":"Soderborg","year":"2018","journal-title":"Nat Commun"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2337\/db10-0979","article-title":"Epigenetic gene promoter methylation at birth is associated with child\u2019s later adiposity","volume":"60","author":"Godfrey","year":"2011","journal-title":"Diabetes"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23205","article-title":"Maternal high-fat feeding primes steatohepatitis in adult mice offspring, involving mitochondrial dysfunction and altered lipogenesis gene expression","volume":"50","author":"Bruce","year":"2009","journal-title":"Hepatology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.3390\/nu15102323","article-title":"Dysregulation of lipid and glucose metabolism in nonalcoholic fatty liver disease","volume":"15","author":"Bhat","year":"2023","journal-title":"Nutrients"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2025.0820","article-title":"Role of amino acids in the regulation of hepatic gluconeogenesis and lipogenesis in metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Kakazu","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3727\/105221618X15156018385515","article-title":"Bile acid metabolism in liver pathobiology","volume":"18","author":"Chiang","year":"2018","journal-title":"Gene Expression"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-022-00941-0","article-title":"The multifaceted role of ferroptosis in liver disease","volume":"29","author":"Chen","year":"2022","journal-title":"Cell Death differentiation"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70091","article-title":"Experimental models to investigate PNPLA3 in liver steatosis","volume":"45","author":"Ramandi","year":"2025","journal-title":"Liver international: Off J Int Assoc Study Liver"},{"key":"B17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/17474124.2022.2032661","article-title":"Research progress on the relationship between TM6SF2 rs58542926 polymorphism and non-alcoholic fatty liver disease","volume":"16","author":"Xue","year":"2022","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.5114\/ceh.2024.136326","article-title":"Association of GCKR and MBOAT7 genetic polymorphisms with non-alcoholic fatty liver disease","volume":"10","author":"Chavan","year":"2024","journal-title":"Clin Exp Hepatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3390\/jpm11070619","article-title":"Is HSD17B13 genetic variant a protector for liver dysfunction? Future perspective as a potential therapeutic target","volume":"11","author":"Motomura","year":"2021","journal-title":"J personalized Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"g4596","DOI":"10.1136\/bmj.g4596","article-title":"Non-alcoholic fatty liver disease","volume":"349","author":"Sattar","year":"2014","journal-title":"BMJ (Clinical Res ed.)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00018-018-2947-0","article-title":"Molecular pathways of nonalcoholic fatty liver disease development and progression","volume":"76","author":"Bessone","year":"2019","journal-title":"Cell Mol Life sciences: CMLS"},{"key":"B22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3892\/etm.2020.9154","article-title":"Abnormal metabolic processes involved in the pathogenesis of non-alcoholic fatty liver disease (Review)","volume":"20","author":"Shao","year":"2020","journal-title":"Exp Ther Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.91863","article-title":"Insulin\u2019s direct hepatic effect explains the inhibition of glucose production caused by insulin secretion","volume":"2","author":"Edgerton","year":"2017","journal-title":"JCI Insight"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/iub.2014","article-title":"3,5-diiodo-L-thyronine increases de novo lipogenesis in liver from hypothyroid rats by SREBP-1 and ChREBP-mediated transcriptional mechanisms","volume":"71","author":"Gnoni","year":"2019","journal-title":"IUBMB Life"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1049818","article-title":"Naringin attenuates fructose-induced NAFLD progression in rats through reducing endogenous triglyceride synthesis and activating the Nrf2\/HO-1 pathway","volume":"13","author":"Pengnet","year":"2022","journal-title":"Front Pharmacol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-023-00809-4","article-title":"The role of ChREBP in carbohydrate sensing and NAFLD development","volume":"19","author":"R\u00e9gnier","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/science.adi3332","article-title":"Hepatic glycogenesis antagonizes lipogenesis by blocking S1P via UDPG","volume":"383","author":"Chen","year":"2024","journal-title":"Sci (New York N.Y.)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28666","article-title":"Hepatocyte mitochondrial DNA released in microparticles and toll-like receptor 9 activation: A link between lipotoxicity and inflammation during nonalcoholic steatohepatitis","volume":"64","author":"Inzaugarat","year":"2016","journal-title":"Hepatology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s12072-020-10121-2","article-title":"How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease","volume":"15","author":"Geng","year":"2021","journal-title":"Hepatol Int"},{"key":"B30","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.plipres.2005.11.002","article-title":"Ceramides in insulin resistance and lipotoxicity","volume":"45","author":"Summers","year":"2006","journal-title":"Prog Lipid Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3390\/jcm10040792","article-title":"Roles of ceramides in non-alcoholic fatty liver disease","volume":"10","author":"Hajduch","year":"2021","journal-title":"J Clin Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"699","DOI":"10.2174\/138955706777435643","article-title":"Ceramide involvement in apoptosis and apoptotic diseases","volume":"6","author":"Thevissen","year":"2006","journal-title":"Mini Rev medicinal Chem"},{"key":"B33","doi-asserted-by":"publisher","first-page":"11128","DOI":"10.3390\/ijms222011128","article-title":"The interplay between insulin resistance, inflammation, oxidative stress, base excision repair and metabolic syndrome in nonalcoholic fatty liver disease","volume":"22","author":"Ziolkowska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201709057","article-title":"Trafficking of cholesterol to the ER is required for NLRP3 inflammasome activation","volume":"217","author":"de la Roche","year":"2018","journal-title":"J Cell Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.248","article-title":"ER stress induces NLRP3 inflammasome activation and hepatocyte death","volume":"6","author":"Lebeaupin","year":"2015","journal-title":"Cell Death Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1199519","article-title":"Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions","volume":"11","author":"Xu","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"457","DOI":"10.4172\/2155-9899.1000457","article-title":"ER stress-induced inflammasome activation contributes to hepatic inflammation and steatosis","volume":"7","author":"Zhang","year":"2016","journal-title":"J Clin Cell Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.3748\/wjg.v29.i25.3999","article-title":"Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis","volume":"29","author":"Pal","year":"2023","journal-title":"World J Gastroenterol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3892\/etm.2021.10138","article-title":"Fatty acids and their role in type-2 diabetes (Review)","volume":"22","author":"Shetty","year":"2021","journal-title":"Exp Ther Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.3390\/nu9101158","article-title":"Fatty acids consumption: the role metabolic aspects involved in obesity and its associated disorders","volume":"9","author":"Silva Figueiredo","year":"2017","journal-title":"Nutrients"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2024.04.006","article-title":"Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease","volume":"36","author":"Bo","year":"2024","journal-title":"Cell Metab"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1000323107","article-title":"mTORC1 activates SREBP-1c and uncouples lipogenesis from gluconeogenesis","volume":"107","author":"Laplante","year":"2010","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2012.03.005","article-title":"Diacylglycerol activation of protein kinase C\u03f5 and hepatic insulin resistance","volume":"15","author":"Jornayvaz","year":"2012","journal-title":"Cell Metab"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.3390\/ijms21061949","article-title":"Excess accumulation of lipid impairs insulin sensitivity in skeletal muscle","volume":"21","author":"Park","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00004.2012","article-title":"More than a store: regulatory roles for glycogen in skeletal muscle adaptation to exercise","volume":"302","author":"Philp","year":"2012","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B46","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2174\/157339909788166864","article-title":"Hyperglycemia induced changes in liver: in vivo and in vitro studies","volume":"5","author":"Dey","year":"2009","journal-title":"Curr Diabetes Rev"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v14.i7.977","article-title":"Implications of receptor for advanced glycation end products for progression from obesity to diabetes and from diabetes to cancer","volume":"14","author":"Garza-Campos","year":"2023","journal-title":"World J Diabetes"},{"key":"B48","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.nutres.2022.04.005","article-title":"Higher hepatic advanced glycation end products and liver damage markers are associated with nonalcoholic steatohepatitis","volume":"104","author":"Priken","year":"2022","journal-title":"Nutr Res (New York N.Y.)"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3390\/nu10101383","article-title":"Regulation and metabolic significance of de novo lipogenesis in adipose tissues","volume":"10","author":"Song","year":"2018","journal-title":"Nutrients"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.70095","article-title":"The impact of fructose consumption on human health: effects on obesity, hyperglycemia, diabetes, uric acid, and oxidative stress with a focus on the liver","volume":"16","author":"Baharuddin","year":"2024","journal-title":"Cureus"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2014.98","article-title":"Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes","volume":"94","author":"Choi","year":"2014","journal-title":"Lab investigation; J Tech Methods Pathol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.399899","article-title":"Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver","volume":"287","author":"Lanaspa","year":"2012","journal-title":"J Biol Chem"},{"key":"B53","doi-asserted-by":"publisher","first-page":"14653","DOI":"10.3390\/ijms241914653","article-title":"Histone modifications in NAFLD: mechanisms and potential therapy","volume":"24","author":"Shi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-021-00614-x","article-title":"The interaction between the gut microbiota and dietary carbohydrates in nonalcoholic fatty liver disease","volume":"53","author":"Park","year":"2021","journal-title":"Exp Mol Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M313478200","article-title":"Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease","volume":"279","author":"Samuel","year":"2004","journal-title":"J Biol Chem"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1172\/JCI21625","article-title":"Increased oxidative stress in obesity and its impact on metabolic syndrome","volume":"114","author":"Furukawa","year":"2004","journal-title":"J Clin Invest"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/nature04634","article-title":"Reactive oxygen species have a causal role in multiple forms of insulin resistance","volume":"440","author":"Houstis","year":"2006","journal-title":"Nature"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1096\/fj.09-151340","article-title":"JNK1 and IKKbeta: molecular links between obesity and metabolic dysfunction","volume":"24","author":"Solinas","year":"2010","journal-title":"FASEB journal: Off Publ Fed Am Societies Exp Biol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26749","article-title":"Adaptive immune responses triggered by oxidative stress contribute to hepatic inflammation in NASH","volume":"59","author":"Sutti","year":"2014","journal-title":"Hepatology"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.057968","article-title":"Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis","volume":"54","author":"Albano","year":"2005","journal-title":"Gut"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-023-2353-0","article-title":"Bile acid signaling in the regulation of whole body metabolic and immunological homeostasis","volume":"67","author":"Jia","year":"2024","journal-title":"Sci China. Life Sci"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1341938","article-title":"Regulating bile acids signaling for NAFLD: molecular insights and novel therapeutic interventions","volume":"15","author":"Wei","year":"2024","journal-title":"Front Microbiol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.1089359","article-title":"The role of bile acid metabolism in the occurrence and development of NAFLD","volume":"9","author":"Bing","year":"2022","journal-title":"Front Mol Biosci"},{"key":"B64","doi-asserted-by":"publisher","first-page":"G554","DOI":"10.1152\/ajpgi.00223.2019","article-title":"Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy","volume":"318","author":"Chiang","year":"2020","journal-title":"Am J Physiol Gastrointestinal liver Physiol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1159\/000371670","article-title":"Bile acids as hormones: the FXR-FGF15\/19 pathway","volume":"33","author":"Kliewer","year":"2015","journal-title":"Digestive Dis (Basel Switzerland)"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","author":"Inagaki","year":"2005","journal-title":"Cell Metab"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2013.08.015","article-title":"Bile acid receptors in non-alcoholic fatty liver disease","volume":"86","author":"Li","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"110024","DOI":"10.1016\/j.abb.2024.110024","article-title":"Role of FXR in the development of NAFLD and intervention strategies of small molecules","volume":"757","author":"Long","year":"2024","journal-title":"Arch Biochem biophysics"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.3390\/biom13091356","article-title":"Alterations in circulating bile acids in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis","volume":"13","author":"Lai","year":"2023","journal-title":"Biomolecules"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23711","article-title":"Hepatic and serum branched-chain fatty acid profile in patients with nonalcoholic fatty liver disease: A case-control study","volume":"31","author":"Mart\u00ednez-Montoro","year":"2023","journal-title":"Obes (Silver Spring Md.)"},{"key":"B71","doi-asserted-by":"publisher","first-page":"959","DOI":"10.3390\/metabo13080959","article-title":"Plasma amino acids in NAFLD patients with obesity are associated with steatosis and fibrosis: results from the MAST4HEALTH study","volume":"13","author":"Amanatidou","year":"2023","journal-title":"Metabolites"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1016\/j.cmet.2024.10.001","article-title":"Amino acid is a major carbon source for hepatic lipogenesis","volume":"36","author":"Liao","year":"2024","journal-title":"Cell Metab"},{"key":"B73","doi-asserted-by":"publisher","first-page":"109581","DOI":"10.1016\/j.jnutbio.2024.109581","article-title":"Molecular mechanism and therapeutic significance of essential amino acids in metabolically associated fatty liver disease","volume":"126","author":"Deng","year":"2024","journal-title":"J Nutr Biochem"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-018-1435-5","article-title":"The profiling of plasma free amino acids and the relationship between serum albumin and plasma-branched chain amino acids in chronic liver disease: a single-center retrospective study","volume":"53","author":"Sano","year":"2018","journal-title":"J Gastroenterol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29465","article-title":"Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance","volume":"67","author":"Gaggini","year":"2018","journal-title":"Hepatology"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1007\/s00726-014-1894-9","article-title":"Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease","volume":"47","author":"Lake","year":"2015","journal-title":"Amino Acids"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.115.118695","article-title":"Serum aminotransferases in nonalcoholic fatty liver disease are a signature of liver metabolic perturbations at the amino acid and Krebs cycle level","volume":"103","author":"Sookoian","year":"2016","journal-title":"Am J Clin Nutr"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29705","article-title":"The nonalcoholic steatohepatitis metabotype: Imbalance of circulating amino acids and transamination reactions reflect impaired mitochondrial function","volume":"67","author":"Sookoian","year":"2018","journal-title":"Hepatology"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz2841","article-title":"Glycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiome","volume":"12","author":"Rom","year":"2020","journal-title":"Sci Trans Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0136822","article-title":"Dysregulated hepatic methionine metabolism drives homocysteine elevation in diet-induced nonalcoholic fatty liver disease","volume":"10","author":"Pacana","year":"2015","journal-title":"PloS One"},{"key":"B81","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jpeds.2016.01.026","article-title":"Amino acid metabolism is altered in adolescents with nonalcoholic fatty liver disease-an untargeted, high resolution metabolomics study","volume":"172","author":"Jin","year":"2016","journal-title":"J Pediatr"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1058101","article-title":"Understanding gut-liver axis nitrogen metabolism in Fatty Liver Disease","volume":"13","author":"Delgado","year":"2022","journal-title":"Front Endocrinol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.12.034","article-title":"A red carpet for iron metabolism","volume":"168","author":"Muckenthaler","year":"2017","journal-title":"Cell"},{"key":"B84","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3390\/ijms17010130","article-title":"Iron homeostasis in health and disease","volume":"17","author":"Gozzelino","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B85","doi-asserted-by":"publisher","first-page":"E767","DOI":"10.1152\/ajpendo.00260.2023","article-title":"Iron metabolism and ferroptosis in nonalcoholic fatty liver disease: what is our next step","volume":"326","author":"Shen","year":"2024","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B86","doi-asserted-by":"publisher","first-page":"155953","DOI":"10.1016\/j.metabol.2024.155953","article-title":"Targeting the regulation of iron homeostasis as a potential therapeutic strategy for nonalcoholic fatty liver disease","volume":"157","author":"Sui","year":"2024","journal-title":"Metabolism: Clin Exp"},{"key":"B87","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s10020-022-00558-6","article-title":"The role of iron metabolism in chronic diseases related to obesity","volume":"28","author":"Qiu","year":"2022","journal-title":"Mol Med (Cambridge Mass.)"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.livres.2022.09.003","article-title":"Iron metabolism in non-alcoholic fatty liver disease: A promising therapeutic target","volume":"6","author":"Chen","year":"2022","journal-title":"Liver Res (Beijing China)"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-024-09908-7","article-title":"Iron homeostasis and insulin sensitivity: unraveling the complex interactions","volume":"25","author":"Sobieska","year":"2024","journal-title":"Rev endocrine Metab Disord"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/87.5.1374","article-title":"Pathways underlying iron accumulation in human nonalcoholic fatty liver disease","volume":"87","author":"Aigner","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29273","article-title":"The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation","volume":"66","author":"BasuRay","year":"2017","journal-title":"Hepatology"},{"key":"B92","doi-asserted-by":"publisher","first-page":"9681","DOI":"10.3390\/ijms24119681","article-title":"PNPLA3-I148M variant promotes the progression of liver fibrosis by inducing mitochondrial dysfunction","volume":"24","author":"Gou","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000001065","article-title":"Human-induced pluripotent stem cell-based hepatic modeling of lipid metabolism-associated TM6SF2-E167K variant","volume":"82","author":"Faccioli","year":"2024","journal-title":"Hepatology"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1247611","article-title":"Glucokinase regulatory protein: a balancing act between glucose and lipid metabolism in NAFLD","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Endocrinol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"102658","DOI":"10.1016\/j.ebiom.2020.102658","article-title":"Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes","volume":"52","author":"Meroni","year":"2020","journal-title":"EBioMedicine"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-320853","article-title":"Loss of hepatic Mboat7 leads to liver fibrosis","volume":"70","author":"Thangapandi","year":"2021","journal-title":"Gut"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712191","article-title":"A protein-truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"New Engl J Med"},{"key":"B98","doi-asserted-by":"publisher","first-page":"102003","DOI":"10.1016\/j.clinre.2022.102003","article-title":"NAFLD: genetics and its clinical implications","volume":"46","author":"Sharma","year":"2022","journal-title":"Clinics Res Hepatol Gastroenterol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.08.012","article-title":"Epidemiology and risk-stratification of NAFLD-associated HCC","volume":"75","author":"Ioannou","year":"2021","journal-title":"J Hepatol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.02.020","article-title":"Update on NAFLD genetics: From new variants to the clinic","volume":"72","author":"Tr\u00e9po","year":"2020","journal-title":"J Hepatol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2021.2018418","article-title":"PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date","volume":"25","author":"Cherubini","year":"2021","journal-title":"Expert Opin Ther Targets"},{"key":"B102","doi-asserted-by":"publisher","first-page":"389","DOI":"10.7555\/JBR.32.20180045","article-title":"Non-alcoholic fatty liver disease: a narrative review of genetics","volume":"32","author":"Danford","year":"2018","journal-title":"J Biomed Res"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2021.11.007","article-title":"TM6SF2\/PNPLA3\/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models","volume":"13","author":"Longo","year":"2022","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.P067454","article-title":"Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study","volume":"58","author":"Krawczyk","year":"2017","journal-title":"J Lipid Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2016.00009","article-title":"PNPLA3 as a genetic determinant of risk for and severity of non-alcoholic fatty liver disease spectrum","volume":"4","author":"Salameh","year":"2016","journal-title":"J Clin Trans Hepatol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jhep.2014.02.030","article-title":"Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma","volume":"61","author":"Liu","year":"2014","journal-title":"J Hepatol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-014-1018-z","article-title":"Effect of PNPLA3 rs738409 variant (I148 M) on hepatic steatosis, necroinflammation, and fibrosis in Japanese patients with chronic hepatitis C","volume":"50","author":"Yasui","year":"2015","journal-title":"J Gastroenterol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1186\/s12879-017-2887-6","article-title":"The rs738409 polymorphism of the PNPLA3 gene is associated with hepatic steatosis and fibrosis in Brazilian patients with chronic hepatitis C","volume":"17","author":"Manchiero","year":"2017","journal-title":"BMC Infect Dis"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-024-10769-0","article-title":"Genetic predisposition of metabolic dysfunction-associated steatotic liver disease: a population-based genome-wide association study","volume":"19","author":"Wang","year":"2025","journal-title":"Hepatol Int"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.06388-11","article-title":"Sam50 functions in mitochondrial intermembrane space bridging and biogenesis of respiratory complexes","volume":"32","author":"Ott","year":"2012","journal-title":"Mol Cell Biol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24283","article-title":"Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease","volume":"53","author":"Sookoian","year":"2011","journal-title":"Hepatology"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1822","article-title":"TM6SF2: A novel genetic player in nonalcoholic fatty liver and cardiovascular disease","volume":"6","author":"Luo","year":"2022","journal-title":"Hepatol Commun"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1323785111","article-title":"TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content","volume":"111","author":"Mahdessian","year":"2014","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat Genet"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1111\/ijpo.12032","article-title":"TM6SF2 Glu167Lys polymorphism is associated with low levels of LDL-cholesterol and increased liver injury in obese children","volume":"11","author":"Grandone","year":"2016","journal-title":"Pediatr Obes"},{"key":"B117","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.1038\/ncomms5309","article-title":"TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease","volume":"5","author":"Liu","year":"2014","journal-title":"Nat Commun"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28142","article-title":"The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta-analysis","volume":"62","author":"Pirola","year":"2015","journal-title":"Hepatology"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011761","article-title":"Effects of GCK, GCKR, G6PC2 and MTNR1B variants on glucose metabolism and insulin secretion","volume":"5","author":"Hu","year":"2010","journal-title":"PloS One"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020555","article-title":"Glucokinase regulatory protein genetic variant interacts with omega-3 PUFA to influence insulin resistance and inflammation in metabolic syndrome","volume":"6","author":"Perez-Martinez","year":"2011","journal-title":"PloS One"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24806","article-title":"Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents","volume":"55","author":"Santoro","year":"2012","journal-title":"Hepatology"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.2174\/1871530320999201126202706","article-title":"Contribution of rs780094 and rs1260326 polymorphisms in GCKR gene to non-alcoholic fatty liver disease: A meta-analysis involving 26,552 participants","volume":"21","author":"Li","year":"2021","journal-title":"Endocrine Metab Immune Disord Drug Targets"},{"key":"B123","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11892-021-01377-5","article-title":"Genetic contribution to non-alcoholic fatty liver disease and prognostic implications","volume":"21","author":"Martin","year":"2021","journal-title":"Curr Diabetes Rep"},{"key":"B124","doi-asserted-by":"publisher","first-page":"10240","DOI":"10.1038\/s41598-019-46750-3","article-title":"An intronic variant in the GCKR gene is associated with multiple lipids","volume":"9","author":"Fernandes Silva","year":"2019","journal-title":"Sci Rep"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12714","article-title":"Common variant in the glucokinase regulatory gene rs780094 and risk of nonalcoholic fatty liver disease: a meta-analysis","volume":"30","author":"Zain","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087523","article-title":"Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease","volume":"9","author":"Petta","year":"2014","journal-title":"PloS One"},{"key":"B127","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s11033-024-09787-w","article-title":"Genotypic variation in CYP2E1, GCKR, and PNPLA3 among nonalcoholic steatohepatitis patients of Turkish origin","volume":"51","author":"Husseini","year":"2024","journal-title":"Mol Biol Rep"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1213916","article-title":"Advances in genetic variation in metabolism-related fatty liver disease","volume":"14","author":"Shi","year":"2023","journal-title":"Front Genet"},{"key":"B129","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1186\/s12876-021-02067-y","article-title":"Association of HSD17B13 rs72613567: TA allelic variant with liver disease: review and meta-analysis","volume":"21","author":"Tang","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.824776","article-title":"HSD17B13: A potential therapeutic target for NAFLD","volume":"8","author":"Zhang","year":"2021","journal-title":"Front Mol Biosci"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30350","article-title":"17-beta hydroxysteroid dehydrogenase 13 is a hepatic retinol dehydrogenase associated with histological features of nonalcoholic fatty liver disease","volume":"69","author":"Ma","year":"2019","journal-title":"Hepatology"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2020.0162","article-title":"Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort","volume":"27","author":"Ting","year":"2021","journal-title":"Clin Mol Hepatol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"194","DOI":"10.14218\/JCTH.2020.00151","article-title":"Associations of hydroxysteroid 17-beta dehydrogenase 13 variants with liver histology in chinese patients with metabolic-associated fatty liver disease","volume":"9","author":"Liu","year":"2021","journal-title":"J Clin Trans Hepatol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"11840","DOI":"10.3390\/ijms231911840","article-title":"Impact of a loss-of-function variant in HSD17B13 on hepatic decompensation and mortality in cirrhotic patients","volume":"23","author":"Gil-G\u00f3mez","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14616","article-title":"Genetic variant rs72613567 of HSD17B13 gene reduces alcohol-related liver disease risk in Chinese Han population","volume":"40","author":"Chen","year":"2020","journal-title":"Liver international: Off J Int Assoc Study Liver"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14495","article-title":"Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non-alcoholic fatty liver disease","volume":"40","author":"Seko","year":"2020","journal-title":"Liver international: Off J Int Assoc Study Liver"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15706","article-title":"MBOAT7 in liver and extrahepatic diseases","volume":"43","author":"Caddeo","year":"2023","journal-title":"Liver international: Off J Int Assoc Study Liver"},{"key":"B138","doi-asserted-by":"publisher","first-page":"RP92243","DOI":"10.7554\/eLife.92243","article-title":"Membrane-bound O-acyltransferase 7 (MBOAT7) shapes lysosomal lipid homeostasis and function to control alcohol-associated liver injury","volume":"12","author":"Varadharajan","year":"2024","journal-title":"eLife"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-023-01497-6","article-title":"Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease","volume":"55","author":"Chen","year":"2023","journal-title":"Nat Genet"},{"key":"B140","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","article-title":"The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of european descent","volume":"150","author":"Mancina","year":"2016","journal-title":"Gastroenterology"},{"key":"B141","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jhep.2020.08.027","article-title":"rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis","volume":"74","author":"Teo","year":"2021","journal-title":"J Hepatol"},{"key":"B142","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000535524","article-title":"Mechanisms and therapeutic strategies for MAFLD targeting TLR4 signaling pathways","volume":"16","author":"Ren","year":"2024","journal-title":"J innate Immun"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1199429","article-title":"MBOAT7 rs641738 (C>T) is associated with NAFLD progression in men and decreased ASCVD risk in elder Chinese population","volume":"14","author":"Xu","year":"2023","journal-title":"Front Endocrinol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2021.01.020","article-title":"Association between MBOAT7 rs641738 polymorphism and non-alcoholic fatty liver in overweight or obese children","volume":"31","author":"Zusi","year":"2021","journal-title":"Nutrition metabolism Cardiovasc diseases: NMCD"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-022-00799-z","article-title":"Liver biopsy for assessment of chronic liver diseases: a synopsis","volume":"23","author":"Chowdhury","year":"2023","journal-title":"Clin Exp Med"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-021-07089-w","article-title":"Incidence of complications from percutaneous biopsy in chronic liver disease: A systematic review and meta-analysis","volume":"67","author":"Thomaides-Brears","year":"2022","journal-title":"Digestive Dis Sci"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2017.1299573","article-title":"Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD)","volume":"10","author":"Han","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.12120896","article-title":"Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis","volume":"267","author":"Tang","year":"2013","journal-title":"Radiology"},{"key":"B149","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.3390\/life13122262","article-title":"Non-invasive diagnostic of NAFLD in type 2 diabetes mellitus and risk stratification: strengths and limitations","volume":"13","author":"Boeriu","year":"2023","journal-title":"Life (Basel Switzerland)"},{"key":"B150","doi-asserted-by":"publisher","first-page":"100381","DOI":"10.1016\/j.jhepr.2021.100381","article-title":"Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates","volume":"3","author":"Garteiser","year":"2021","journal-title":"JHEP reports: Innovation Hepatol"},{"key":"B151","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.3390\/diagnostics14222517","article-title":"Sequential diagnostic approach using FIB-4 and ELF for predicting advanced fibrosis in metabolic dysfunction-associated steatotic liver disease","volume":"14","author":"Kang","year":"2024","journal-title":"Diagnostics (Basel Switzerland)"},{"key":"B152","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3390\/life11020143","article-title":"FIB-4 first in the diagnostic algorithm of metabolic-dysfunction-associated fatty liver disease in the era of the global metabodemic","volume":"11","author":"Sumida","year":"2021","journal-title":"Life (Basel Switzerland)"},{"key":"B153","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1016\/j.cgh.2021.12.034","article-title":"Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population","volume":"20","author":"Graupera","year":"2022","journal-title":"Clin Gastroenterol hepatology: Off Clin Pract J Am Gastroenterological Assoc"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.01256","article-title":"Cell-free circulating nucleic acids as early biomarkers for NAFLD and NAFLD-associated disorders","volume":"9","author":"Turchinovich","year":"2018","journal-title":"Front Physiol"},{"key":"B155","doi-asserted-by":"publisher","first-page":"5888","DOI":"10.3390\/ijms21165888","article-title":"History of nonalcoholic fatty liver disease","volume":"21","author":"Lonardo","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B156","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1053\/j.gastro.2023.11.018","article-title":"PNPLA3 risk allele association with ALT response to semaglutide treatment","volume":"166","author":"Urias","year":"2024","journal-title":"Gastroenterology"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-024-04007-8","article-title":"The effect of dulaglutide on glycated hemoglobin is associated with PNPLA3 I148M gene polymorphism in patients with type 2 diabetes mellitus","volume":"87","author":"Gavriilidis","year":"2025","journal-title":"Endocrine"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000890","article-title":"The effects of diet and lifestyle interventions on insulin resistance in patients with nonalcoholic fatty liver disease: a systematic review","volume":"29","author":"Paris","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B159","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12937-024-00968-8","article-title":"A comprehensive approach to lifestyle intervention based on a calorie-restricted diet ameliorates liver fat in overweight\/obese patients with NAFLD: a multicenter randomized controlled trial in China","volume":"23","author":"Liu","year":"2024","journal-title":"Nutr J"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15314","article-title":"Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications","volume":"50","author":"Jayakumar","year":"2019","journal-title":"Alimentary Pharmacol Ther"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: Pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J Hepatol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.997018","article-title":"Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications","volume":"12","author":"Fang","year":"2022","journal-title":"Front Cell infection Microbiol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2019.1681861","article-title":"Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis","volume":"11","author":"Astbury","year":"2020","journal-title":"Gut Microbes"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-019-0156-z","article-title":"Gut microbial metabolites in obesity, NAFLD and T2DM","volume":"15","author":"Canfora","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.761836","article-title":"Gut microbiome-mediated alteration of immunity, inflammation, and metabolism involved in the regulation of non-alcoholic fatty liver disease","volume":"12","author":"He","year":"2021","journal-title":"Front Microbiol"},{"key":"B166","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease","volume":"25","author":"Loomba","year":"2017","journal-title":"Cell Metab"},{"key":"B167","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41577-019-0198-4","article-title":"The intestinal microbiota fuelling metabolic inflammation","volume":"20","author":"Tilg","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02045-0","article-title":"Resmetirom: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.07.003","article-title":"Expert panel recommendations: practical clinical applications for initiating and monitoring resmetirom in patients with MASH\/NASH and moderate to noncirrhotic advanced fibrosis","volume":"22","author":"Noureddin","year":"2024","journal-title":"Clin Gastroenterol hepatology: Off Clin Pract J Am Gastroenterological Assoc"},{"key":"B170","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000607","article-title":"A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis","volume":"79","author":"Rinella","year":"2024","journal-title":"Hepatology"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00017-6","article-title":"Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2\/3): a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"7","author":"Harrison","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2024.00123","article-title":"Pipeline of new drug treatment for non-alcoholic fatty liver disease\/metabolic dysfunction-associated steatotic liver disease","volume":"12","author":"Hu","year":"2024","journal-title":"J Clin Trans Hepatol"},{"key":"B174","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.1038\/s41467-023-42162-0","article-title":"ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib\/IIa trial","volume":"14","author":"Hu","year":"2023","journal-title":"Nat Commun"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 Agonist, for treatment of NAFLD: A randomized controlled double-blind phase 2 trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"B176","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J Hepatol"},{"key":"B177","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/hep.31108","article-title":"Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study","volume":"72","author":"Ratziu","year":"2020","journal-title":"Hepatology"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajcnut.2024.07.013","article-title":"Quercetin intervention reduced hepatic fat deposition in patients with nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled crossover clinical trial","volume":"120","author":"Li","year":"2024","journal-title":"Am J Clin Nutr"},{"key":"B179","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ajcnut.2024.05.017","article-title":"Curcumin supplementation alleviates hepatic fat content associated with modulation of gut microbiota-dependent bile acid metabolism in patients with nonalcoholic simple fatty liver disease: a randomized controlled trial","volume":"120","author":"He","year":"2024","journal-title":"Am J Clin Nutr"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1080\/09168451.2020.1793293","article-title":"Effect and mechanism of ginsenoside Rg1-regulating hepatic steatosis in HepG2 cells induced by free fatty acid","volume":"84","author":"Gao","year":"2020","journal-title":"Bioscience biotechnology Biochem"},{"key":"B181","doi-asserted-by":"publisher","first-page":"9299574","DOI":"10.1155\/2022\/9299574","article-title":"Oxidative stress and ginsenosides: an update on the molecular mechanisms","volume":"2022","author":"He","year":"2022","journal-title":"Oxid Med Cell Longevity"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.08.010","article-title":"Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice","volume":"41","author":"Leclercq","year":"2004","journal-title":"J Hepatol"},{"key":"B183","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12986-019-0410-3","article-title":"Curcumin prevents high-fat diet-induced hepatic steatosis in ApoE(-\/-) mice by improving intestinal barrier function and reducing endotoxin and liver TLR4\/NF-\u03baB inflammation","volume":"16","author":"Feng","year":"2019","journal-title":"Nutr Metab"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2021.e07324","article-title":"Quercetin enhances fatty acid \u03b2-oxidation by inducing lipophagy in AML12 hepatocytes","volume":"7","author":"Fukaya","year":"2021","journal-title":"Heliyon"},{"key":"B185","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.3390\/nu10101457","article-title":"Gut microbiota\u2019s relationship with liver disease and role in hepatoprotection by dietary natural products and probiotics","volume":"10","author":"Meng","year":"2018","journal-title":"Nutrients"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2014.02.001","article-title":"Insights into drug discovery from natural medicines using reverse pharmacokinetics","volume":"35","author":"Hao","year":"2014","journal-title":"Trends Pharmacol Sci"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1639064\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T04:18:00Z","timestamp":1757477880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1639064\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":186,"alternative-id":["10.3389\/fendo.2025.1639064"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1639064","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]},"article-number":"1639064"}}